Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
CC BY-NC-ND 4.0 · Thromb Haemost 2022; 122(07): 1115-1129
DOI: 10.1055/a-1788-5322
DOI: 10.1055/a-1788-5322
Cellular Haemostasis and Platelets
Cucurbitacins Elicit Anti-Platelet Activity via Perturbation of the Cytoskeleton and Integrin Function
Funding This work was supported by a British Heart Foundation Project Grant PG/2019/34798 (to A.J.U.) and British Heart Foundation programme grants RG/15/2/31224 and RG/20/7/34866 (to J.M.G.), and research funds from the Centre for Bioscience at Manchester Metropolitan University and a Manchester Metropolitan University Internal Research Accelerator Grant: 343846 (to A.J.U.).
Abstract
Cucurbitacins are dietary compounds that have been shown to elicit a range of anti-tumour, anti-inflammatory and anti-atherosclerotic activities. Originally identified as signal transducer and activator of transcription, STAT, inhibitors, a variety of mechanisms of action have since been described, including dysregulation of the actin cytoskeleton and disruption of integrin function. Integrin outside-in signalling and cytoskeletal rearrangements are critical for the propagation of stable thrombus formation and clot retraction following platelet adhesion at the site of vessel damage. The effects of cucurbitacins on platelet function and thrombus formation are unknown. We report for the first time anti-platelet and anti-thrombotic effects of cucurbitacins B, E and I in human platelets. Treatment of platelets with cucurbitacins resulted in attenuation of platelet aggregation, secretion and fibrinogen binding following stimulation by platelet agonists. Cucurbitacins were also found to potently inhibit other integrin- and cytoskeleton-mediated events, including adhesion, spreading and clot retraction. Further investigation of cytoskeletal dynamics found treatment with cucurbitacins altered cofilin phosphorylation, enhanced activation and increased F actin polymerisation and microtubule assembly. Disruption to cytoskeletal dynamics has been previously shown to impair integrin activation, platelet spreading and clot retraction. Anti-platelet properties of cucurbitacins were found to extend to a disruption of stable thrombus formation, with an increase in thrombi instability and de-aggregation under flow. Our research identifies novel, anti-platelet and anti-thrombotic actions of cucurbitacins that appear to be linked to dysregulation of cytoskeletal dynamics and integrin function.
Author Contributions
Contribution: N.K., S.N., T.S., B.K., A.P.B., J.L.M., S.T., performed experiments and analysed results. M.G.M., S.J. and J.M.G. designed the research and wrote the paper. A.J.U. designed the research, performed experiments, analysed results and wrote the paper.
Publication History
Received: 18 May 2021
Accepted: 06 November 2021
Accepted Manuscript online:
04 March 2022
Article published online:
30 July 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Kaushik U, Aeri V, Mir SR. Cucurbitacins - an insight into medicinal leads from nature. Pharmacogn Rev 2015; 9 (17) 12-18
- 2 Stainer AR, Sasikumar P, Bye AP. et al. The metabolites of the dietary flavonoid quercetin possess potent antithrombotic activity, and interact with aspirin to enhance antiplatelet effects. TH Open 2019; 3 (03) e244-e258
- 3 Vaiyapuri S, Ali MS, Moraes LA. et al. Tangeretin regulates platelet function through inhibition of phosphoinositide 3-kinase and cyclic nucleotide signaling. Arterioscler Thromb Vasc Biol 2013; 33 (12) 2740-2749
- 4 Vaiyapuri S, Roweth H, Ali MS. et al. Pharmacological actions of nobiletin in the modulation of platelet function. Br J Pharmacol 2015; 172 (16) 4133-4145
- 5 Ed Nignpense B, Chinkwo KA, Blanchard CL, Santhakumar AB. Polyphenols: modulators of platelet function and platelet microparticle generation?. Int J Mol Sci 2019; 21 (01) E146
- 6 Kaneider NC, Mosheimer B, Reinisch N, Patsch JR, Wiedermann CJ. Inhibition of thrombin-induced signaling by resveratrol and quercetin: effects on adenosine nucleotide metabolism in endothelial cells and platelet-neutrophil interactions. Thromb Res 2004; 114 (03) 185-194
- 7 Chen X, Bao J, Guo J. et al. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. Anticancer Drugs 2012; 23 (08) 777-787
- 8 Alghasham AA. Cucurbitacins - a promising target for cancer therapy. Int J Health Sci (Qassim) 2013; 7 (01) 77-89
- 9 Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63 (06) 1270-1279
- 10 Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005; 24 (20) 3236-3245
- 11 Nakashima S, Matsuda H, Kurume A. et al. Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells. Bioorg Med Chem Lett 2010; 20 (09) 2994-2997
- 12 Zhang YT, Xu LH, Lu Q. et al. VASP activation via the Gα13/RhoA/PKA pathway mediates cucurbitacin-B-induced actin aggregation and cofilin-actin rod formation. PLoS One 2014; 9 (04) e93547
- 13 Kong Y, Chen J, Zhou Z, Xia H, Qiu MH, Chen C. Cucurbitacin E induces cell cycle G2/M phase arrest and apoptosis in triple negative breast cancer. PLoS One 2014; 9 (07) e103760
- 14 Jayaprakasam B, Seeram NP, Nair MG. Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett 2003; 189 (01) 11-16
- 15 McFarland BC, Gray GK, Nozell SE, Hong SW, Benveniste EN. Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells. Mol Cancer Res 2013; 11 (05) 494-505
- 16 Wang X, Tanaka M, Peixoto HS, Wink M. Cucurbitacins: elucidation of their interactions with the cytoskeleton. PeerJ 2017; 5: e3357
- 17 Touihri-Barakati I, Kallech-Ziri O, Ayadi W. et al. Cucurbitacin B purified from Ecballium elaterium (L.) A. Rich from Tunisia inhibits α5β1 integrin-mediated adhesion, migration, proliferation of human glioblastoma cell line and angiogenesis. Eur J Pharmacol 2017; 797: 153-161
- 18 Gupta P, Srivastava SK. Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. Oncotarget 2014; 5 (07) 1812-1828
- 19 Gong H, Shen B, Flevaris P. et al. G protein subunit Galpha13 binds to integrin alphaIIbbeta3 and mediates integrin “outside-in” signaling. Science 2010; 327 (5963): 340-343
- 20 Durrant TN, van den Bosch MT, Hers I. Integrin αIIbβ3 outside-in signaling. Blood 2017; 130 (14) 1607-1619
- 21 Shin EK, Park H, Noh JY, Lim KM, Chung JH. Platelet shape changes and cytoskeleton dynamics as novel therapeutic targets for anti-thrombotic drugs. Biomol Ther (Seoul) 2017; 25 (03) 223-230
- 22 Bye AP, Unsworth AJ, Gibbins JM. Platelet signaling: a complex interplay between inhibitory and activatory networks. J Thromb Haemost 2016; 14 (05) 918-930
- 23 Ni H, Freedman J. Platelets in hemostasis and thrombosis: role of integrins and their ligands. Transfus Apheresis Sci 2003; 28 (03) 257-264
- 24 Moraes LA, Spyridon M, Kaiser WJ. et al. Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation. J Thromb Haemost 2010; 8 (03) 577-587
- 25 Vaiyapuri S, Jones CI, Sasikumar P. et al. Gap junctions and connexin hemichannels underpin hemostasis and thrombosis. Circulation 2012; 125 (20) 2479-2491
- 26 Wei H, Davies JE, Harper MT. 2-Aminoethoxydiphenylborate (2-APB) inhibits release of phosphatidylserine-exposing extracellular vesicles from platelets. Cell Death Discov 2020; 6: 10
- 27 Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260 (06) 3440-3450
- 28 Poenie M. Alteration of intracellular Fura-2 fluorescence by viscosity: a simple correction. Cell Calcium 1990; 11 (2-3): 85-91
- 29 Bye AP, Unsworth AJ, Vaiyapuri S, Stainer AR, Fry MJ, Gibbins JM. Ibrutinib inhibits platelet integrin αIIbβ3 outside-in signaling and thrombus stability but not adhesion to collagen. Arterioscler Thromb Vasc Biol 2015; 35 (11) 2326-2335
- 30 Kanaji T, Kanaji S, Montgomery RR, Patel SB, Newman PJ. Platelet hyperreactivity explains the bleeding abnormality and macrothrombocytopenia in a murine model of sitosterolemia. Blood 2013; 122 (15) 2732-2742
- 31 Pugh N, Maddox BD, Bihan D, Taylor KA, Mahaut-Smith MP, Farndale RW. Differential integrin activity mediated by platelet collagen receptor engagement under flow conditions. Thromb Haemost 2017; 117 (08) 1588-1600
- 32 Unsworth AJ, Bye AP, Sage T. et al. Antiplatelet properties of Pim kinase inhibition are mediated through disruption of thromboxane A2 receptor signaling. Haematologica 2021; 106 (07) 1968-1978
- 33 Bye AP, Unsworth AJ, Desborough MJ. et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv 2017; 1 (26) 2610-2623
- 34 Pugh N, Bihan D, Perry DJ, Farndale RW. Dynamic analysis of platelet deposition to resolve platelet adhesion receptor activity in whole blood at arterial shear rate. Platelets 2015; 26 (03) 216-219
- 35 Khan AO, Slater A, Maclachlan A. et al. Post-translational polymodification of β1-tubulin regulates motor protein localisation in platelet production and function. Haematologica 2022; 107 (01) 243-259
- 36 Wersäll A, Williams CM, Brown E, Iannitti T, Williams N, Poole AW. Mouse platelet Ral GTPases control P-selectin surface expression, regulating platelet-leukocyte interaction. Arterioscler Thromb Vasc Biol 2018; 38 (04) 787-800
- 37 Flaumenhaft R, Dilks JR, Rozenvayn N, Monahan-Earley RA, Feng D, Dvorak AM. The actin cytoskeleton differentially regulates platelet alpha-granule and dense-granule secretion. Blood 2005; 105 (10) 3879-3887
- 38 Woronowicz K, Dilks JR, Rozenvayn N. et al. The platelet actin cytoskeleton associates with SNAREs and participates in alpha-granule secretion. Biochemistry 2010; 49 (21) 4533-4542
- 39 Duncan MD, Duncan KL. Cucurbitacin E targets proliferating endothelia. J Surg Res 1997; 69 (01) 55-60
- 40 Bury L, Falcinelli E, Chiasserini D, Springer TA, Italiano Jr JE, Gresele P. Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia. Haematologica 2016; 101 (01) 46-56
- 41 Cauwenberghs S, Feijge MA, Harper AG, Sage SO, Curvers J, Heemskerk JW. Shedding of procoagulant microparticles from unstimulated platelets by integrin-mediated destabilization of actin cytoskeleton. FEBS Lett 2006; 580 (22) 5313-5320
- 42 Sari-Hassoun M, Clement MJ, Hamdi I. et al. Cucurbitacin I elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhibition of LIM-kinase. Biochem Pharmacol 2016; 102: 45-63
- 43 Pandey D, Goyal P, Bamburg JR, Siess W. Regulation of LIM-kinase 1 and cofilin in thrombin-stimulated platelets. Blood 2006; 107 (02) 575-583
- 44 Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics 2011; 1: 154-188
- 45 Chew DP, Bhatt DL, Topol EJ. Oral glycoprotein IIb/IIIa inhibitors: why don't they work?. Am J Cardiovasc Drugs 2001; 1 (06) 421-428
- 46 Cox D. Oral GPIIb/IIIa antagonists: what went wrong?. Curr Pharm Des 2004; 10 (14) 1587-1596
- 47 Bennett JS, Zigmond S, Vilaire G, Cunningham ME, Bednar B. The platelet cytoskeleton regulates the affinity of the integrin alpha(IIb)beta(3) for fibrinogen. J Biol Chem 1999; 274 (36) 25301-25307
- 48 Aburima A, Walladbegi K, Wake JD, Naseem KM. cGMP signaling inhibits platelet shape change through regulation of the RhoA-Rho Kinase-MLC phosphatase signaling pathway. J Thromb Haemost 2017; 15 (08) 1668-1678
- 49 Falet H, Chang G, Brohard-Bohn B, Rendu F, Hartwig JH. Integrin alpha(IIb)beta3 signals lead cofilin to accelerate platelet actin dynamics. Am J Physiol Cell Physiol 2005; 289 (04) C819-C825
- 50 Zhang M, Bian ZG, Zhang Y. et al. Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells. Mol Med Rep 2014; 10 (06) 2905-2911
- 51 Beutler JA. Natural products as a foundation for drug discovery. Curr Protocols Pharmacol 2019; 86 (01) e67
- 52 Guo Z. The modification of natural products for medical use. Acta Pharm Sin B 2017; 7 (02) 119-136
- 53 Gehringer M, Laufer SA. Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology. J Med Chem 2019; 62 (12) 5673-5724
- 54 Kumar A, Zhang KYJ. Advances in the development of shape similarity methods and their application in drug discovery. Front Chem 2018; 6: 315
- 55 Guvench O. Computational functional group mapping for drug discovery. Drug Discov Today 2016; 21 (12) 1928-1931